JP2024507253A - Tyk2阻害剤およびその使用 - Google Patents
Tyk2阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2024507253A JP2024507253A JP2023550553A JP2023550553A JP2024507253A JP 2024507253 A JP2024507253 A JP 2024507253A JP 2023550553 A JP2023550553 A JP 2023550553A JP 2023550553 A JP2023550553 A JP 2023550553A JP 2024507253 A JP2024507253 A JP 2024507253A
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- methyl
- pharmaceutically acceptable
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163151287P | 2021-02-19 | 2021-02-19 | |
| US63/151,287 | 2021-02-19 | ||
| US202163193514P | 2021-05-26 | 2021-05-26 | |
| US63/193,514 | 2021-05-26 | ||
| PCT/IB2022/000062 WO2022175746A1 (en) | 2021-02-19 | 2022-02-16 | Tyk2 inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507253A true JP2024507253A (ja) | 2024-02-16 |
| JP2024507253A5 JP2024507253A5 (cg-RX-API-DMAC7.html) | 2025-02-05 |
Family
ID=80786684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550553A Pending JP2024507253A (ja) | 2021-02-19 | 2022-02-16 | Tyk2阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12600721B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4294806A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024507253A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230159420A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022223497A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023016678A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL305127A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023009723A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202302583A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022175746A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024508789A (ja) * | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | Tyk2阻害剤およびその使用 |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| US20260055121A1 (en) * | 2022-08-24 | 2026-02-26 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| JP2025539787A (ja) * | 2022-11-16 | 2025-12-09 | ヴァーンウィ セラピューティクス,インコーポレイテッド | Tyk2阻害剤 |
| WO2024246602A1 (en) * | 2023-05-26 | 2024-12-05 | Sudo Biosciences Limited | Fused azoled as tyk2 inhibitors and uses thereof |
| WO2026035922A1 (en) * | 2024-08-08 | 2026-02-12 | V6 Therapeutics, Inc. | Selective jak2 inhibitors and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017500291A (ja) * | 2013-11-19 | 2017-01-05 | ユニヴェルシテ・ドゥ・ストラスブールUniversite De Strasbourg | ヒトアセチルコリンエステラーゼのop阻害に対する新規な非電荷の再活性化剤 |
| WO2018151830A1 (en) * | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US37650A (en) | 1863-02-10 | Improvement in apparatus for obtaining profiles of submarine beds | ||
| US36256A (en) | 1862-08-19 | Improvement in sewing-m ach ines | ||
| US47929A (en) | 1865-05-30 | Improved grapnel for wells | ||
| EP0124081A3 (en) | 1983-05-02 | 1986-11-26 | Merck & Co. Inc. | New substituted cephalosporin sulfones as antiinflammatory and antidegenerative agents, pharmaceutical compositions containing the same and processes for making them |
| US5132301A (en) | 1983-05-02 | 1992-07-21 | Merck & Co., Inc. | Substituted cephalosporin sulfones as anti-inflammatory and anti-degenerative agents |
| USRE37650E1 (en) | 1991-05-10 | 2002-04-09 | Aventis Pharmacetical Products, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| DE69222637T2 (de) | 1991-05-10 | 1998-02-26 | Rhone Poulenc Rorer Int | Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US6645969B1 (en) | 1991-05-10 | 2003-11-11 | Aventis Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| EP0541042A1 (de) | 1991-11-05 | 1993-05-12 | Hoechst Aktiengesellschaft | Pyridin-2,4- und 2,5-dicarbonsäureamide und deren Derivate, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| DE69819903T2 (de) | 1997-08-09 | 2004-11-11 | Smithkline Beecham P.L.C., Brentford | Bicyclische verbindungen als liganden der 5-ht1 rezeptoren |
| DE10134721A1 (de) | 2001-07-17 | 2003-02-06 | Bayer Ag | Tetrahydrochinoxaline |
| JP2005509028A (ja) | 2001-10-09 | 2005-04-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法 |
| KR100577179B1 (ko) | 2001-10-30 | 2006-05-10 | 엘지전자 주식회사 | 유기 전계 발광 소자 |
| US7078409B2 (en) | 2002-03-28 | 2006-07-18 | Beta Pharma, Inc. | Fused quinazoline derivatives useful as tyrosine kinase inhibitors |
| DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
| CA2755297A1 (en) | 2003-02-10 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Processes for the preparation of n-heteroaryl-n-aryl-amines by reacting an n-aryl carbamic acid ester with a halo-heteroaryl and analogous processes |
| CN100579965C (zh) | 2003-02-10 | 2010-01-13 | 沃泰克斯药物股份有限公司 | 通过使n-芳基氨基甲酸酯与卤代杂芳基反应制备n-杂芳基-n-芳基胺的方法和类似方法 |
| DE102004009238A1 (de) | 2004-02-26 | 2005-09-08 | Merck Patent Gmbh | Arylamid-Derivate |
| ATE524182T1 (de) | 2005-04-21 | 2011-09-15 | Merck Serono Sa | 2,3-substituierte pyrazinsulfonamide als crth2- hemmer |
| KR20080058436A (ko) | 2005-10-13 | 2008-06-25 | 와이어쓰 | 글루탐산 유도체의 제조 방법 |
| ATE541844T1 (de) | 2005-12-21 | 2012-02-15 | Abbott Lab | Antivirale verbindungen |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| JP5546450B2 (ja) | 2007-05-21 | 2014-07-09 | オスラム オプト セミコンダクターズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 燐光発光金属錯体化合物、燐光発光金属錯体化合物を含有する発光素子、及び、燐光発光金属錯体化合物の製造法 |
| TWI418608B (zh) | 2007-09-28 | 2013-12-11 | Osram Opto Semiconductors Gmbh | 有機輻射發射元件 |
| WO2009069132A2 (en) | 2007-11-29 | 2009-06-04 | Ramot At Tel Aviv University Ltd. | Novel reverse transcriptase inhibitors |
| EP2231143B1 (en) | 2007-12-13 | 2013-07-03 | Merck Sharp & Dohme Corp. | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES |
| KR20100132550A (ko) * | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | syk 또는 JAK 키나제 억제제로서의 2,6-디아미노-피리미딘-5-일-카르복스아미드 |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| US20130225527A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| GB0813403D0 (en) | 2008-07-22 | 2008-08-27 | Lectus Therapeutics Ltd | Potassium ion channel modulators & uses thereof |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| DE102008061214A1 (de) | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
| EP2206712A1 (en) | 2008-12-23 | 2010-07-14 | CHIESI FARMACEUTICI S.p.A. | "Alkaloid aminoester derivatives and medicinal composition thereof" |
| WO2010100144A1 (en) | 2009-03-04 | 2010-09-10 | Merck Serono S.A. | Fused bicyclic compounds as inhibitors for pi3 kinase |
| WO2011026579A1 (en) | 2009-09-04 | 2011-03-10 | Bayer Schering Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| WO2011056957A2 (en) | 2009-11-06 | 2011-05-12 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
| WO2011113060A2 (en) | 2010-03-12 | 2011-09-15 | Trana Discovery, Inc. | Antiviral compounds and methods of use thereof |
| JP2013538821A (ja) | 2010-09-24 | 2013-10-17 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 |
| WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| GB201107176D0 (en) | 2011-04-28 | 2011-06-15 | Cxr Biosciences Ltd | Pyrrolnitrin derivatives |
| WO2012172043A1 (en) | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections |
| NO3175985T3 (cg-RX-API-DMAC7.html) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| WO2013005057A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | New compounds |
| WO2013004984A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Tricyclic compounds for use as kinase inhibitors |
| WO2013005041A1 (en) | 2011-07-07 | 2013-01-10 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Tricyclic heterocyclic compounds as kinase inhibitors |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| CA2874987A1 (en) | 2012-06-01 | 2013-12-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US9853756B2 (en) | 2012-11-07 | 2017-12-26 | Qualcomm Incorporated | Multicast over wireless network with the assistance of power-efficient peer group discovery |
| HRP20220766T1 (hr) | 2012-11-08 | 2022-09-16 | Bristol-Myers Squibb Company | Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora |
| EP2922841B8 (en) | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
| CA2890935A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha. |
| WO2014120683A1 (en) | 2013-01-29 | 2014-08-07 | Children's Hospital Medical Center | Small-molecule inhibitors targeting g-protein-coupled rho guanine nucleotide exchange factors |
| CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| WO2015013715A2 (en) | 2013-07-26 | 2015-01-29 | Thr Regents Of The University Of California | C-h fluorination of heterocycles with silver (ii) fluoride |
| WO2015129927A1 (en) | 2014-02-26 | 2015-09-03 | Kyorin Pharmaceutical Co., Ltd. | Heterocyclic compounds |
| GB201405359D0 (en) | 2014-03-25 | 2014-05-07 | Univ Liverpool | Synthetic process |
| GB2533925A (en) | 2014-12-31 | 2016-07-13 | Univ Bath | Antimicrobial compounds, compositions and methods |
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2016149756A1 (en) | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| EP3290418B1 (en) | 2015-04-29 | 2019-05-15 | Wuxi Fortune Pharmaceutical Co., Ltd | Janus kinase (jak) inhibitors |
| TW201705961A (zh) | 2015-06-11 | 2017-02-16 | 阿爾米雷爾有限公司 | 作為jak抑制劑的2-(吡唑并吡啶-3-基)嘧啶衍生物 |
| WO2016207345A1 (en) | 2015-06-24 | 2016-12-29 | Pierre Fabre Medicament | 3-amino-pyrazin-2-yl carboxamide and 2-amino-pyridin-3-yl carboxamide derivatives as polo-like kinase 1 (plk-1) inhibitors for the treatment of cancer |
| WO2017005832A1 (en) | 2015-07-09 | 2017-01-12 | Solvay Specialty Polymers Italy S.P.A. | Process for the synthesis of (per)fluoropolyether amines |
| KR101726059B1 (ko) | 2015-07-28 | 2017-04-12 | 한양대학교 산학협력단 | 디피롤 유도체와 암모늄 염을 포함하는 브롬화수소 가스 검출용 조성물 및 이를 포함하는 브롬화수소 가스 검출용 색변환 센서 |
| KR101766961B1 (ko) | 2015-07-28 | 2017-08-09 | 한양대학교 산학협력단 | 트리페닐이미다졸 유도체와 암모늄 염을 포함하는 메틸아민 가스 검출용 조성물 및 이를 포함하는 메틸아민 가스 검출용 색변환 센서 |
| GB201513481D0 (en) | 2015-07-30 | 2015-09-16 | Univ Manchester | Inhibitor compounds |
| MX2018008169A (es) | 2015-12-30 | 2019-02-20 | Agios Pharmaceuticals Inc | Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante. |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| BR112018070494A2 (pt) | 2016-04-06 | 2019-01-29 | Koninklijke Philips Nv | carimbo para um processo de litografia por impressão, método de fabricação de um carimbo, kit de peças para a fabricação de um carimbo, método de formação de uma camada dotada de um padrão e uso de um carimbo |
| CN105820175B (zh) | 2016-04-13 | 2019-09-20 | 四川大学 | 一种噻吩并嘧啶类化合物及其制备方法和应用 |
| IL307931A (en) | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| CA3158951A1 (en) | 2016-08-15 | 2018-02-22 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
| CN107880038B (zh) | 2016-09-30 | 2021-09-28 | 中国医药研究开发中心有限公司 | [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途 |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| GB201704327D0 (en) | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
| AU2018243749A1 (en) | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN109020957B (zh) | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
| EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| US20210213014A1 (en) | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
| AU2018353150B2 (en) | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| GB201717260D0 (en) | 2017-10-20 | 2017-12-06 | Galapagos Nv | Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders |
| MY202167A (en) | 2017-11-21 | 2024-04-12 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| US11479555B2 (en) | 2018-02-23 | 2022-10-25 | Newave Pharmaceutical Inc. | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase |
| WO2019209182A1 (en) | 2018-04-25 | 2019-10-31 | Nanyang Technological University | Conjugated oligoelectrolytes as antimicrobial agents |
| WO2019226991A1 (en) | 2018-05-25 | 2019-11-28 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| JP2021536458A (ja) | 2018-09-04 | 2021-12-27 | マジェンタ セラピューティクス インコーポレイテッドMagenta Therapeutics, Inc. | アリール炭化水素レセプター・アンタゴニスト及び使用方法 |
| JP2022508651A (ja) | 2018-10-08 | 2022-01-19 | レヴォリューション・メディスンズ,インコーポレイテッド | 癌を処置するためのshp2阻害剤組成物および方法 |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| US12098117B2 (en) | 2018-12-11 | 2024-09-24 | Duke University | Compositions and methods for the treatment of cancer |
| EP3673920A1 (en) | 2018-12-28 | 2020-07-01 | Universität Wien | Polyphenol-peptide conjugates for nuclear-targeted delivery |
| KR102943760B1 (ko) | 2019-01-28 | 2026-03-26 | 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 | 피리다진 유도체 억제제, 및 그의 제조 방법 및 용도 |
| CN111484480B (zh) | 2019-01-29 | 2023-08-11 | 上海翰森生物医药科技有限公司 | 一种多环类衍生物抑制剂、其制备方法和应用 |
| GB201903085D0 (en) | 2019-03-07 | 2019-04-24 | Univ Oxford Innovation Ltd | Passivation method |
| US20220177459A1 (en) | 2019-04-02 | 2022-06-09 | Hinova Pharmaceuticals Inc. | Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators |
| WO2020222773A1 (en) | 2019-04-30 | 2020-11-05 | Celgene Corporation | Combination therapies comprising apremilast and tyk2 inhibitors |
| CN112079830B (zh) | 2019-06-14 | 2023-12-22 | 上海翰森生物医药科技有限公司 | 含并环类衍生物抑制剂、其制备方法和应用 |
| KR102877616B1 (ko) | 2019-07-01 | 2025-10-28 | 삼성디스플레이 주식회사 | 조성물 및 이를 포함한 유기 발광 소자 |
| WO2021001739A1 (en) | 2019-07-02 | 2021-01-07 | Effector Therapeutics, Inc. | Translational enhancers and related methods |
| WO2021014453A1 (en) | 2019-07-24 | 2021-01-28 | Sol-Gel Technologies Ltd. | Topical jak inhibitor combination compositions for treatment of inflammatory skin conditions |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| IL291452B1 (en) | 2019-09-18 | 2026-06-01 | Bristol Myers Squibb Co | Dosage forms for TYK2 inhibitors |
| CN112851579A (zh) | 2019-11-27 | 2021-05-28 | 衡阳师范学院 | 用于铜催化卤代芳烃偶联反应的配体化合物、催化体系和偶联反应 |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US20230128972A1 (en) | 2020-01-31 | 2023-04-27 | Atomwise Inc. | Anat Inhibitors and Methods of Use Thereof |
| ES2981764T3 (es) | 2020-03-11 | 2024-10-10 | Beijing Innocare Pharma Tech Co Ltd | Compuestos heterocíclicos para inhibir las actividades de TYK2 |
| KR20230004771A (ko) | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn알파 조정제로서의 치환된 n-(메틸-d3)피리다진-3-카르복스아미드 또는 n-(메틸-d3)-니코틴아미드 화합물 |
| IL298966A (en) | 2020-06-11 | 2023-02-01 | Betta Pharmaceuticals Co Ltd | Bicyclic compound and application thereof |
| CN115667246B (zh) | 2020-07-24 | 2024-08-23 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物自由碱的晶型及其制备方法和应用 |
| CN113968846A (zh) | 2020-07-24 | 2022-01-25 | 上海翰森生物医药科技有限公司 | 一种哒嗪类衍生物的盐、晶型及其制备方法和应用 |
| US20220144842A1 (en) | 2020-11-04 | 2022-05-12 | Eternity Bioscience Inc. | Irak inhibitors, preparation method and medicinal uses thereof |
| US20230416225A1 (en) | 2020-11-09 | 2023-12-28 | Merck Sharp & Dohme Llc | Diaminopyrimidine carboxamide inhibitors of hpk1 |
| US12668594B2 (en) | 2020-12-23 | 2026-06-30 | Sudo Biosciences Limited | TYK2 inhibitors and uses thereof |
| KR20230159421A (ko) | 2021-02-19 | 2023-11-21 | 수도 바이오사이언시즈 리미티드 | Tyk2 억제제 및 이의 용도 |
| IL305119A (en) | 2021-02-19 | 2023-10-01 | Sudo Biosciences Ltd | Tyk2 inhibitors and uses thereof |
| TW202302583A (zh) | 2021-02-19 | 2023-01-16 | 英商蘇多生物科學有限公司 | Tyk2抑制劑及其用途 |
| WO2022175745A1 (en) | 2021-02-19 | 2022-08-25 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| JP2022143679A (ja) | 2021-03-18 | 2022-10-03 | 株式会社リコー | 光電変換素子、電子機器、及び電源モジュール |
| US12054506B2 (en) | 2021-03-19 | 2024-08-06 | Singular Genomics Systems, Inc. | Reducing agents and uses thereof |
| WO2022226349A1 (en) | 2021-04-22 | 2022-10-27 | Essa Pharma, Inc. | Androgen receptor modulators and methods for their use |
| US12560054B2 (en) | 2021-04-30 | 2026-02-24 | Board Of Regents, The University Of Texas System | Use of carboxylates for carbon sequestration, improved oil recovery, and hydrogen storage and reproduction |
| KR20240008338A (ko) | 2021-05-14 | 2024-01-18 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| US20240317718A1 (en) | 2021-05-14 | 2024-09-26 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| KR20240007242A (ko) | 2021-05-14 | 2024-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 헤테로시클릭 화합물 |
| PE20250262A1 (es) | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| EP4337650A1 (en) | 2021-05-14 | 2024-03-20 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2023227946A1 (en) | 2022-05-27 | 2023-11-30 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| US20260055121A1 (en) | 2022-08-24 | 2026-02-26 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| WO2024246602A1 (en) | 2023-05-26 | 2024-12-05 | Sudo Biosciences Limited | Fused azoled as tyk2 inhibitors and uses thereof |
| IL324864A (en) | 2023-05-26 | 2026-01-01 | Sudo Biosciences Ltd | Compressed azines as tyk2 inhibitors and their uses |
| WO2025114761A1 (en) | 2023-11-29 | 2025-06-05 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| IL328235A (en) | 2023-11-29 | 2026-07-01 | Sudo Biosciences Ltd | TYK2 inhibitors and their uses |
-
2022
- 2022-02-16 TW TW111105572A patent/TW202302583A/zh unknown
- 2022-02-16 WO PCT/IB2022/000062 patent/WO2022175746A1/en not_active Ceased
- 2022-02-16 KR KR1020237031676A patent/KR20230159420A/ko active Pending
- 2022-02-16 BR BR112023016678A patent/BR112023016678A2/pt unknown
- 2022-02-16 US US18/546,943 patent/US12600721B2/en active Active
- 2022-02-16 IL IL305127A patent/IL305127A/en unknown
- 2022-02-16 MX MX2023009723A patent/MX2023009723A/es unknown
- 2022-02-16 EP EP22711297.6A patent/EP4294806A1/en active Pending
- 2022-02-16 AU AU2022223497A patent/AU2022223497A1/en active Pending
- 2022-02-16 JP JP2023550553A patent/JP2024507253A/ja active Pending
-
2026
- 2026-03-03 US US19/555,454 patent/US20260193259A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017500291A (ja) * | 2013-11-19 | 2017-01-05 | ユニヴェルシテ・ドゥ・ストラスブールUniversite De Strasbourg | ヒトアセチルコリンエステラーゼのop阻害に対する新規な非電荷の再活性化剤 |
| WO2018151830A1 (en) * | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024508789A (ja) * | 2021-02-19 | 2024-02-28 | スドー バイオサイエンシーズ リミテッド | Tyk2阻害剤およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022175746A1 (en) | 2022-08-25 |
| AU2022223497A1 (en) | 2023-09-21 |
| US20260193259A1 (en) | 2026-07-09 |
| WO2022175746A8 (en) | 2023-10-19 |
| BR112023016678A2 (pt) | 2023-11-14 |
| TW202302583A (zh) | 2023-01-16 |
| KR20230159420A (ko) | 2023-11-21 |
| MX2023009723A (es) | 2023-10-30 |
| US20240199610A1 (en) | 2024-06-20 |
| IL305127A (en) | 2023-10-01 |
| US12600721B2 (en) | 2026-04-14 |
| EP4294806A1 (en) | 2023-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024508794A (ja) | Tyk2阻害剤およびその使用 | |
| US12103937B2 (en) | Substituted pyridines and pyridazines as TYK2 inhibitors | |
| US12600721B2 (en) | TYK2 inhibitors and uses thereof | |
| WO2022175745A1 (en) | Tyk2 inhibitors and uses thereof | |
| KR20260018891A (ko) | Tyk2 억제제로서의 축합된 아진 및 이의 용도 | |
| WO2024042361A1 (en) | Tyk2 inhibitors and uses thereof | |
| CN117377669A (zh) | Tyk2抑制剂及其用途 | |
| WO2025114761A1 (en) | Tyk2 inhibitors and uses thereof | |
| CN117120440A (zh) | Tyk2抑制剂及其用途 | |
| CA3208507A1 (en) | Tyk2 inhibitors and uses thereof | |
| CN117242072A (zh) | Tyk2抑制剂及其用途 | |
| EA052918B1 (ru) | Ингибиторы tyk2 и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231020 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250128 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250128 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250929 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251205 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260330 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260513 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260807 |